Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 993-1002

  Ghosn, Jade ^a   Carosi, Giampiero ^b   Moreno, Santiago ^c   Pokrovsky, Vadim ^d   Lazzarin, Adriano ^e   Pialoux, Gilles ^f   Sanz Moreno, Jose ^g   Balogh, Agnes ^h   Vandeloise, Eric ^h   Biguenet, Sophie ^h   Leleu, Ghislaine ^h   Delfraissy, Jean Francois ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HÔPITAL TENON   (France)

^g HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; BILIRUBIN; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EYE JAUNDICE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RANDOM ALLOCATION; RITONAVIR; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 78651113527     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1666     Document Type: Article

References (30)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. (Updated 3 November 2008. Accessed September 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
2. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
3. Reyataz® (atazanavir sulfate). Package Insert 2009. Bristol-Myers Squibb, Uxbridge, UK.
4. Reyataz® (atazanavir sulfate). Highlights of prescribing information. Package Insert 2008. Bristol-Myers Squibb, Uxbridge, UK. (Updated September 2008. Accessed 08 September 2010.) Available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/021567s017lbl.pdf
5. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
6. Johnson MA, Gathe JC, Jr., Podzamczer D, et al. A oncedaily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-160.
7. Cooper D, Zajdenverg R, Ruxrungtham K, Chavez RL. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33. HIV8, 8th International Congress on Drug Therapy in HIV infection. 12-16 November 2006, Glasgow, UK. Abstract 444.
8. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
9. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718.
10. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61:200-205.
11. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51:29-36.
12. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492.
13. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005; 39:174-180.
14. Jackson A, Patel N, Lo G, Gazzard B, Moyle G. Effects of atazanavir or saquinavir once daily with ritonavir 100mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 818.
15. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009; 23:1349-1357.
16. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47:161-167. (Pubitemid 351172182)
17. Behrens GM, Reiss P. Abacavir and caridiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
18. Strategies for Management of Anti-Retroviral Therapy/INSIGHT and the DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
19. van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS ONE 2009; 4:e5647.
20. Garrido C, Soriano V, de Mendoza C. New therapeutic strategies for raltegravir. J Antimicrob Chemother 2010; 65:218-223.
21. Allavena C, Mounoury O, Rodallec A, et al. Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials 2009; 10:337-340.
22. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50:605-612.
23. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240.
24. Asboe D, Williams IG, Goodall RL, Darbyshire JH, Hooker MH, Babiker AG. A virological benefit from an induction/maintenance strategy: the Forte trial. Antivir Ther 2007; 12:47-54.
25. Squires K. Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WELBB103.
26. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
27. Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive subjects with screening HIV RNA ≥100,000 c/ml. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract THAB0303.
28. Valantin MA, de Truchis P, Bittar R, et al. Switching NRTI backbone to tenofovir plus emtricitabine (Truvada) promptly improves triglycerides and LDL-cholesterol levels in dyslipidemic HIV patients: the TOTEM randomised trial. 17th International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract THPE0156.
29. Soriano V, Köppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract LBPE07.
30. Electronic Medicines Compendium. Reyataz® 150 mg, 200 mg and 300 mg hard capsules. (Updated 12 August 2010. Accessed 8 September 2010.) Available from http://www.medicines.org.uk/emc/medicine/14145/